Khursheed Anwer, PhD, MBA, assumed the title of Executive Vice President and Chief Science Officer, upon Celsion’s June 2014 acquisition of EGEN, Inc., where he was President and Chief Science Officer, a position he held since 2009. He joined EGEN, Inc. in July, 2002, as Vice President of Research and Development, and directed the company’s clinical and research and development functions throughout his tenure at EGEN, Inc. Dr. Anwer has a PhD in Physiology/Pharmacology from Ohio University and received postdoctoral training from the University of Texas Health Science Center at Houston. Before joining EGEN, Inc., Dr. Anwer was Director of Pre-Clinical Development at Valentis, Inc. From 1993 to 1999, he served in several positions at GeneMedicine, Inc., where he led several research projects in the area of nonviral gene therapy. He has authored more than 40 publications in the area of nonviral gene therapy, resulting from his active career in research and development. Dr. Anwer has served as an adjunct faculty member in the Biology Department at the University of Alabama in Huntsville and a board member of the University of Alabama Business School, STEP.